CTU Chad Therapeutics,

CHAD Therapeutics, Inc. (AMEX:CTU) today announced the launch of an advanced pneumatic oxygen conserver and its next-generation oxygen transfilling system at the Medtrade show in Las Vegas. CHAD's advanced BONSAITM pneumatic conserver is an important addition to the Company's extensive line of oxygen conserving devices. "With its sleek, lightweight design (less than 10 ounces), conserving ratio of up to 6:1, eight settings, and an adjustable continuous flow feature, BONSAI reinforces CHAD's longstanding leadership in the oxygen conserver market. A pneumatic conserving device that offers a 6:1 savings ratio while ensuring adequate oxygen saturation for patients is a groundbreaking achievement," said President and CEO Earl Yager. CHAD currently expects to receive FDA clearance to market and be able to begin shipping this new device in May. Yager continued, "CHAD's next-generation oxygen transfilling system, the OMNI line, is a significant upgrade to CHAD's pioneering TOTAL O2� Home Oxygen Delivery System that meets the needs of a broader range of oxygen patients than ever before and gives homecare providers a powerful tool to reduce operating costs and take advantage of the new Medicare transfilling reimbursement category that took effect on January 1, 2007." The OMNI 2 is designed for the specific requirements of pediatric patients. The OMNI 5 offers increased oxygen delivery of up to 5 liters per minute. In addition to providing stationary oxygen, both devices can also refill a wide variety of portable oxygen cylinders in the patient's home, thus eliminating the cost for the homecare provider and inconvenience for the patient of having to periodically collect and refill oxygen cylinders at a remote depot. "Our new BONSAI and OMNI devices demonstrate CHAD's commitment to technology that improves patient care while lowering operating costs for homecare providers," the CEO added. About CHAD Therapeutics CHAD Therapeutics, Inc. develops, manufactures and markets respiratory care devices designed to improve the efficiency of oxygen delivery systems for home health care and hospital treatment of patients suffering from pulmonary diseases. For more information, visit www.CHADtherapeutics.com. Safe Harbor Statements under the Private Securities Litigation Reform Act of 1995. The foregoing statements regarding prospects for future earnings and revenues, future sales trends and the introduction of products under development are forward-looking statements that involve certain risks and uncertainties. A number of important factors could cause actual results to differ materially from those contemplated by such forward-looking statements. These include the loss of one or more major customers, increased competition, the introduction of new products with perceived competitive advantages over the Company's products, changes or proposed changes in health care reimbursement which affect home care providers and CHAD's ability to anticipate and respond to technological and economic changes in the home oxygen market. Moreover, the success of the Company's products and products under development will depend on their efficacy, reliability and the health care community's perception of the products' capabilities and benefits, the degree of acceptance the products achieve among homecare providers and, with respect to products under development, obtaining timely regulatory approval. Additional factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Company's annual and quarterly reports filed with the Securities and Exchange Commission under the caption "Outlook: Issues and Risks."